JP2019509063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509063A5 JP2019509063A5 JP2018568183A JP2018568183A JP2019509063A5 JP 2019509063 A5 JP2019509063 A5 JP 2019509063A5 JP 2018568183 A JP2018568183 A JP 2018568183A JP 2018568183 A JP2018568183 A JP 2018568183A JP 2019509063 A5 JP2019509063 A5 JP 2019509063A5
- Authority
- JP
- Japan
- Prior art keywords
- replication
- recombinant retrovirus
- cells
- incompetent recombinant
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001430294 unidentified retrovirus Species 0.000 claims 35
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 16
- 210000000822 natural killer cell Anatomy 0.000 claims 13
- 230000001589 lymphoproliferative effect Effects 0.000 claims 12
- 230000035897 transcription Effects 0.000 claims 8
- 238000013518 transcription Methods 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- 230000010076 replication Effects 0.000 claims 7
- 230000011664 signaling Effects 0.000 claims 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 5
- 239000012528 membrane Substances 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000031146 intracellular signal transduction Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000011541 reaction mixture Substances 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 claims 2
- 101710091045 Envelope protein Proteins 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 101710188315 Protein X Proteins 0.000 claims 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000034217 membrane fusion Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 230000026683 transduction Effects 0.000 claims 2
- 238000010361 transduction Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 241000714162 Feline endogenous virus Species 0.000 claims 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 claims 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 claims 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 1
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 101150099493 STAT3 gene Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022062818A JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2024064510A JP2024086884A (ja) | 2016-03-19 | 2024-04-12 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662390093P | 2016-03-19 | 2016-03-19 | |
| US62/390,093 | 2016-03-19 | ||
| US201662360041P | 2016-07-08 | 2016-07-08 | |
| US62/360,041 | 2016-07-08 | ||
| US201762467039P | 2017-03-03 | 2017-03-03 | |
| US62/467,039 | 2017-03-03 | ||
| PCT/US2017/023112 WO2017165245A2 (en) | 2016-03-19 | 2017-03-19 | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062818A Division JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509063A JP2019509063A (ja) | 2019-04-04 |
| JP2019509063A5 true JP2019509063A5 (https=) | 2020-04-30 |
| JP7108551B2 JP7108551B2 (ja) | 2022-07-28 |
Family
ID=58461483
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568183A Active JP7108551B2 (ja) | 2016-03-19 | 2017-03-19 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2022062818A Active JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2024064510A Pending JP2024086884A (ja) | 2016-03-19 | 2024-04-12 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062818A Active JP7474281B2 (ja) | 2016-03-19 | 2022-04-05 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
| JP2024064510A Pending JP2024086884A (ja) | 2016-03-19 | 2024-04-12 | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10596274B2 (https=) |
| EP (1) | EP3430136A2 (https=) |
| JP (3) | JP7108551B2 (https=) |
| KR (1) | KR102457098B1 (https=) |
| CN (2) | CN108884460B (https=) |
| AU (2) | AU2017236796B2 (https=) |
| CA (1) | CA3017378A1 (https=) |
| CU (1) | CU24649B1 (https=) |
| IL (1) | IL261713B2 (https=) |
| MX (2) | MX2018011345A (https=) |
| RU (1) | RU2755059C2 (https=) |
| SG (2) | SG10202104509PA (https=) |
| WO (1) | WO2017165245A2 (https=) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450112B2 (en) | 2008-04-09 | 2013-05-28 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| US11248238B2 (en) | 2015-10-22 | 2022-02-15 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| PL3443012T3 (pl) | 2016-04-15 | 2026-04-20 | Bioatla, Inc. | Przeciwciała anty-axl, fragmenty przeciwciał i ich immunokoniugaty oraz ich zastosowania |
| US11377637B2 (en) | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| GB201614093D0 (en) * | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
| SG11201901642XA (en) | 2016-08-26 | 2019-03-28 | Baylor College Medicine | Constitutively active cytokine receptors for cell therapy |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US11261428B2 (en) | 2018-03-15 | 2022-03-01 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| AU2017370644A1 (en) * | 2016-12-05 | 2019-06-13 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| WO2018136566A1 (en) | 2017-01-18 | 2018-07-26 | F1 Oncology, Inc. | Methods of transducing and expanding immune cells and uses thereof |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| AU2018226884B2 (en) * | 2017-03-03 | 2024-11-07 | Exuma Biotech, Corp. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2018161026A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il15 compositions and methods for immunotherapy |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| CN111479921B (zh) * | 2017-09-18 | 2024-08-02 | 埃克苏马生物技术公司 | 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物 |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
| AU2018385699B2 (en) * | 2017-12-14 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Daric interleukin receptors |
| JP2021509903A (ja) * | 2018-01-05 | 2021-04-08 | マックスサイト インコーポレーティッド | 癌の長期ｃａｒ処置 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CA3091478A1 (en) * | 2018-02-17 | 2019-08-22 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| CN112262214A (zh) * | 2018-04-12 | 2021-01-22 | 优莫佳生物制药股份有限公司 | 病毒载体及包装细胞系 |
| SG11202010116PA (en) | 2018-04-13 | 2020-11-27 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
| CN110499291B (zh) * | 2018-05-16 | 2023-11-24 | 上海赛比曼生物科技有限公司 | 无血清培养制备嵌合抗原受体t细胞的方法 |
| US20200109364A1 (en) * | 2018-05-31 | 2020-04-09 | Washington University | Methods for genome-editing and activation of cells |
| CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| EP3820509A1 (en) | 2018-07-09 | 2021-05-19 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| CA3109959A1 (en) * | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| AU2019333324B2 (en) * | 2018-09-02 | 2025-08-28 | Exuma Biotech, Corp | Methods and compositions for genetically modifying lymphocytes in blood or in enriched PBMCs |
| WO2020076730A1 (en) * | 2018-10-08 | 2020-04-16 | Amberstone Biosciences, Inc. | Compartmentalized assays of bispecific and multispecific biologics |
| WO2020092696A1 (en) * | 2018-10-31 | 2020-05-07 | Musc Foundation For Research Development | Ex vivo activation and expansion of t cells for adoptive cell transfer therapy |
| WO2020102503A2 (en) * | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| US12496274B2 (en) | 2018-11-14 | 2025-12-16 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for compartment-specific cargo delivery |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| WO2020146899A1 (en) * | 2019-01-11 | 2020-07-16 | Chan Zuckerberg Biohub, Inc. | Targeted in vivo genome modification |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US12440513B2 (en) | 2019-03-22 | 2025-10-14 | Albany Medical College | Methods for improving cognitive function |
| JP7633180B2 (ja) * | 2019-05-02 | 2025-02-19 | セリアド オンコロジー エス．アー． | マルチプレックス化干渉ｒｎａを有する細胞 |
| KR20220031554A (ko) * | 2019-05-08 | 2022-03-11 | 인히브릭스, 인크. | Cd33 표적화 면역요법 |
| JP2022546101A (ja) * | 2019-09-01 | 2022-11-02 | エクスマ バイオテック コーポレイション | リンパ球の改変および送達のための方法および組成物 |
| WO2021044439A1 (en) * | 2019-09-08 | 2021-03-11 | Immunoadaptive Cell Therapy Pvt Ltd. | Inducible cytokine signals & methods for immunotherapy |
| US20240122978A1 (en) * | 2019-10-16 | 2024-04-18 | Umoja Biopharma, Inc. | Retroviral vector for univeral receptor therapy |
| CN112779223B (zh) * | 2019-11-08 | 2024-06-11 | 浙江煦顼技术有限公司 | 偶联嵌合抗原受体细胞及其用途 |
| IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| WO2021113270A1 (en) * | 2019-12-02 | 2021-06-10 | Shape Therapeutics Inc. | Therapeutic editing |
| CA3160759A1 (en) * | 2019-12-05 | 2021-06-10 | Vycellix, Inc. | Modulators of the immune escape mechanism for universal cell therapy |
| WO2021142376A1 (en) * | 2020-01-08 | 2021-07-15 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| US20230348624A1 (en) | 2020-01-30 | 2023-11-02 | Umoja Biopharma, Inc. | Bispecific transduction enhancer |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| EP4114400A4 (en) * | 2020-03-05 | 2023-10-18 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| CN115968300A (zh) * | 2020-05-11 | 2023-04-14 | 艾宾妥斯生物公司 | 用于体内转导的载体和方法 |
| CN112592408B (zh) * | 2020-07-20 | 2021-08-17 | 北京鼎成肽源生物技术有限公司 | 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| CN115380112B (zh) * | 2020-11-02 | 2024-03-29 | 上海医药集团生物治疗技术有限公司 | 两个或多个靶点嵌合抗原受体基因工程载体及其应用 |
| MX2023008831A (es) | 2021-01-27 | 2023-10-19 | Umoja Biopharma Inc | Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19. |
| AU2022212090A1 (en) | 2021-01-28 | 2023-07-06 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
| IL307544A (en) | 2021-04-08 | 2023-12-01 | Sana Biotechnology Inc | Cd8-specific antibody constructs and compositions thereof |
| EP4319812A4 (en) * | 2021-04-08 | 2025-07-09 | Scripps Research Inst | NEW THERAPIES WITH MODIFIED EFFECTOR CELLS |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| EP4377453A4 (en) * | 2021-07-26 | 2025-09-03 | Georgia Tech Res Inst | COMPOSITIONS AND METHODS FOR IN VIVO PROTEASE PROFILING BY DISPLAYING IMMUNE CELLS |
| EP4435101A4 (en) * | 2021-11-17 | 2025-11-12 | Shanghai Juncell Therapeutics Co Ltd | MEMBRANE SURFACE PROTEIN CONTAINING A GPI ANCHOR REGION |
| JP2024546145A (ja) * | 2021-12-22 | 2024-12-17 | クレ．エーアイ，インク． | 迅速ｔ－細胞製造 |
| US20250099612A1 (en) | 2022-03-01 | 2025-03-27 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| WO2023230276A1 (en) * | 2022-05-27 | 2023-11-30 | Kite Pharma, Inc. | Compositions and methods for preparing engineered lymphocytes for cell therapy |
| CN120359048A (zh) * | 2022-09-02 | 2025-07-22 | 美洛德生物医药公司 | 用于细胞特异性表达的组合物及其用途 |
| CN120417889A (zh) * | 2022-09-22 | 2025-08-01 | 美洛德生物医药公司 | 工程化嵌合融合蛋白组合物及其使用方法 |
| CN115807020A (zh) * | 2022-09-23 | 2023-03-17 | 卡瑞济(北京)生命科技有限公司 | 白介素15受体α装甲CAR-T细胞在降低白介素15诱导的细胞毒性中的用途 |
| CN116731974B (zh) * | 2023-05-23 | 2024-11-29 | 杭州荣谷生物科技有限公司 | 病毒的制备方法和应用 |
| WO2024259051A1 (en) * | 2023-06-14 | 2024-12-19 | The Children's Medical Center Corporation | Systems and methods for modifying a polynucleotide |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| FR2713657B1 (fr) * | 1993-12-13 | 1996-03-01 | Transgene Sa | Nouveaux vecteurs pour le traitement du sida. |
| KR20060099543A (ko) | 1994-12-09 | 2006-09-19 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의 동정 |
| AUPR074500A0 (en) * | 2000-10-13 | 2000-11-09 | Monash University | Treatment of t cell disorders |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| JP2008518630A (ja) | 2004-11-08 | 2008-06-05 | イェール ユニバーシティ | リボスイッチ、リボスイッチによる、構造を基礎とする化合物設計、ならびにリボスイッチの使用方法およびリボスイッチを伴う組成物 |
| SG174103A1 (en) * | 2007-05-29 | 2011-09-29 | Univ Yale | Riboswitches and methods and compositions for use of and with riboswitches |
| US9464284B2 (en) | 2009-03-09 | 2016-10-11 | Bioatla, Llc | Mirac proteins |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| CN107164330A (zh) * | 2011-04-08 | 2017-09-15 | 贝勒医学院 | 使用嵌合细胞因子受体逆转肿瘤微环境的影响 |
| GB201107768D0 (en) * | 2011-05-10 | 2011-06-22 | Univ Manchester | Riboswitches |
| WO2013092720A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| DK3763820T3 (da) * | 2012-02-29 | 2022-02-07 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Retroviral transduktion ved hjælp af poloxamerer |
| EP3447072A3 (en) | 2013-03-05 | 2019-05-22 | Baylor College of Medicine | Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy |
| EP2997107B1 (en) * | 2013-05-14 | 2018-06-20 | 3M Innovative Properties Company | Adhesive composition |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CN106068326B (zh) | 2013-10-28 | 2021-06-18 | 联邦高等教育系统-匹兹堡大学 | 溶瘤性hsv载体 |
| KR102048855B1 (ko) | 2014-07-29 | 2019-11-26 | 셀렉티스 | 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체 |
| WO2016033331A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| GB201503500D0 (en) * | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| EP3322801A1 (en) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| EP3472318B1 (en) * | 2016-07-08 | 2023-09-06 | Exuma Biotech Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| AU2018226884B2 (en) * | 2017-03-03 | 2024-11-07 | Exuma Biotech, Corp. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
-
2017
- 2017-03-19 IL IL261713A patent/IL261713B2/en unknown
- 2017-03-19 EP EP17714989.5A patent/EP3430136A2/en active Pending
- 2017-03-19 KR KR1020187029258A patent/KR102457098B1/ko active Active
- 2017-03-19 CU CU2018000109A patent/CU24649B1/es unknown
- 2017-03-19 JP JP2018568183A patent/JP7108551B2/ja active Active
- 2017-03-19 CN CN201780018352.1A patent/CN108884460B/zh active Active
- 2017-03-19 MX MX2018011345A patent/MX2018011345A/es unknown
- 2017-03-19 US US15/462,855 patent/US10596274B2/en active Active
- 2017-03-19 RU RU2018136607A patent/RU2755059C2/ru active
- 2017-03-19 SG SG10202104509PA patent/SG10202104509PA/en unknown
- 2017-03-19 AU AU2017236796A patent/AU2017236796B2/en active Active
- 2017-03-19 WO PCT/US2017/023112 patent/WO2017165245A2/en not_active Ceased
- 2017-03-19 CA CA3017378A patent/CA3017378A1/en active Pending
- 2017-03-19 CN CN202310365875.0A patent/CN116426490A/zh active Pending
- 2017-03-19 SG SG11201807286WA patent/SG11201807286WA/en unknown
-
2018
- 2018-09-18 MX MX2025000222A patent/MX2025000222A/es unknown
-
2021
- 2021-10-14 AU AU2021250935A patent/AU2021250935A1/en active Pending
-
2022
- 2022-04-05 JP JP2022062818A patent/JP7474281B2/ja active Active
-
2024
- 2024-04-12 JP JP2024064510A patent/JP2024086884A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509063A5 (https=) | ||
| JP2018506983A5 (https=) | ||
| JP2023060000A (ja) | レトロウイルスおよびレンチウイルスベクター | |
| RU2018136607A (ru) | Способы и составы для производства лимфоцитов и их регулируемого увеличения | |
| CN110506060B (zh) | 嵌合分子及其用途 | |
| JP5553989B2 (ja) | ウィルスベクターを使用した標的化遺伝子送達方法 | |
| JP2020074776A5 (https=) | ||
| JP2017528158A5 (https=) | ||
| JP2008538174A5 (https=) | ||
| WO2018033726A1 (en) | Retroviral and lentiviral vectors | |
| JP7221049B2 (ja) | レンチウイルス調製物の安定化のための緩衝液 | |
| JP2019512251A5 (https=) | ||
| JP2019150066A5 (https=) | ||
| JP2019514373A (ja) | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 | |
| JP2009201525A5 (https=) | ||
| JP2017537622A5 (https=) | ||
| RU2017111298A (ru) | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 | |
| WO2014016383A2 (en) | Glycoproteins for pseudotyping lentivectors | |
| EP4602174A1 (en) | Viral particles targeting hematopoietic stem cells | |
| Froelich et al. | Lentiviral vectors for immune cells targeting | |
| WO2024044655A1 (en) | Delivery of heterologous proteins | |
| Schneider et al. | Regulation of the Borna disease virus polymerase complex by the viral nucleoprotein p38 isoform | |
| JP2012110290A5 (https=) | ||
| WO2023210616A1 (ja) | Ｒｎａウイルス由来のキメラエンベロープタンパク質及び該タンパク質を持つｒｎａウイルスベクター | |
| EP4698665A1 (en) | Engineered protein g fusogens and related lipid particles and methods thereof |